BACKGROUND: Cancer treatment is associated with decline in measured and self-reported physical function and increased pain. In the current study, the authors evaluated the impact of a walking intervention on these outcomes during chemotherapy/radiation. METHODS:Patients with breast, prostate, and other cancers (N=126) were randomized to a home-based walking intervention (exercise) or usual care (control). Exercise dose during the intervention was assessed using a 5-item Physical Activity Questionnaire. Outcome measures were cardiorespiratory fitness, expressed as peak oxygen uptake (VO2) measured during treadmill testing (n=85) or estimated by 12-minute walk (n=27), and self-reported physical function, role limitations, and pain derived from Medical Outcomes Study Short Form 36. Linear regression was used to evaluate pre-to-post intervention change outcomes between groups. RESULTS: The mean (standard deviation) age of the patients was 60.2 (10.6) years. Diagnoses included prostate (55.6%) and breast (32.5%) cancer. Treatment included external beam radiotherapy (52.3%) and chemotherapy (34.9%). Exercise patients reported worsening Medical Outcomes Study physical function role limitations by the end of cancer treatment (P=.037). Younger age was associated with improved Medical Outcomes Study physical function (P=.048). In all patients, increased exercise dose was associated with decreased Medical Outcomes Study pain (P=.046), regardless of diagnosis. The percent change of VO2 between prostate and nonprostate cancer patients when adjusted for baseline VO2 and Physical Activity Questionnaire values was 17.45% (P=.008), with better VO2 maintenance in the prostate group. CONCLUSIONS:Exercise during cancer treatment improves cardiorespiratory fitness and self-reported physical function in prostate cancer patients and in younger patients, regardless of diagnosis, and may attenuate loss of those capacities in patients undergoing chemotherapy. Exercise also reduces the pain experience. Copyright (c) 2009 American Cancer Society.
RCT Entities:
BACKGROUND:Cancer treatment is associated with decline in measured and self-reported physical function and increased pain. In the current study, the authors evaluated the impact of a walking intervention on these outcomes during chemotherapy/radiation. METHODS:Patients with breast, prostate, and other cancers (N=126) were randomized to a home-based walking intervention (exercise) or usual care (control). Exercise dose during the intervention was assessed using a 5-item Physical Activity Questionnaire. Outcome measures were cardiorespiratory fitness, expressed as peak oxygen uptake (VO2) measured during treadmill testing (n=85) or estimated by 12-minute walk (n=27), and self-reported physical function, role limitations, and pain derived from Medical Outcomes Study Short Form 36. Linear regression was used to evaluate pre-to-post intervention change outcomes between groups. RESULTS: The mean (standard deviation) age of the patients was 60.2 (10.6) years. Diagnoses included prostate (55.6%) and breast (32.5%) cancer. Treatment included external beam radiotherapy (52.3%) and chemotherapy (34.9%). Exercise patients reported worsening Medical Outcomes Study physical function role limitations by the end of cancer treatment (P=.037). Younger age was associated with improved Medical Outcomes Study physical function (P=.048). In all patients, increased exercise dose was associated with decreased Medical Outcomes Study pain (P=.046), regardless of diagnosis. The percent change of VO2 between prostate and nonprostate cancer patients when adjusted for baseline VO2 and Physical Activity Questionnaire values was 17.45% (P=.008), with better VO2 maintenance in the prostate group. CONCLUSIONS: Exercise during cancer treatment improves cardiorespiratory fitness and self-reported physical function in prostate cancerpatients and in younger patients, regardless of diagnosis, and may attenuate loss of those capacities in patients undergoing chemotherapy. Exercise also reduces the pain experience. Copyright (c) 2009 American Cancer Society.
Authors: N J Vogelzang; W Breitbart; D Cella; G A Curt; J E Groopman; S J Horning; L M Itri; D H Johnson; S L Scherr; R K Portenoy Journal: Semin Hematol Date: 1997-07 Impact factor: 3.851
Authors: Carol Sweeney; Kathryn H Schmitz; DeAnn Lazovich; Beth A Virnig; Robert B Wallace; Aaron R Folsom Journal: J Natl Cancer Inst Date: 2006-04-19 Impact factor: 13.506
Authors: M L Segar; V L Katch; R S Roth; A W Garcia; T I Portner; S G Glickman; S Haslanger; E G Wilkins Journal: Oncol Nurs Forum Date: 1998 Jan-Feb Impact factor: 2.172
Authors: Kirsten K Ness; Melanie M Wall; J Michael Oakes; Leslie L Robison; James G Gurney Journal: Ann Epidemiol Date: 2005-08-30 Impact factor: 3.797
Authors: V Mock; K H Dow; C J Meares; P M Grimm; J A Dienemann; M E Haisfield-Wolfe; W Quitasol; S Mitchell; A Chakravarthy; I Gage Journal: Oncol Nurs Forum Date: 1997-07 Impact factor: 2.172
Authors: Ji Hye Hwang; Hyun Jung Chang; Young Hun Shim; Won Hah Park; Won Park; Seung Jae Huh; Jung-Hyun Yang Journal: Yonsei Med J Date: 2008-06-30 Impact factor: 2.759
Authors: Cindy L Carter; Georgiana Onicescu; Kathleen B Cartmell; Katherine R Sterba; James Tomsic; Anthony J Alberg Journal: Support Care Cancer Date: 2011-09-20 Impact factor: 3.603
Authors: Karin Oechsle; Wiebke Jensen; Tobias Schmidt; Rüdiger Reer; Klaus-Michael Braumann; Maike de Wit; Carsten Bokemeyer Journal: Support Care Cancer Date: 2010-03-31 Impact factor: 3.603
Authors: Ana D Goode; Sheleigh P Lawler; Charlotte L Brakenridge; Marina M Reeves; Elizabeth G Eakin Journal: J Cancer Surviv Date: 2015-03-11 Impact factor: 4.442
Authors: Maria C Swartz; Zakkoyya H Lewis; Elizabeth J Lyons; Kristofer Jennings; Addie Middleton; Rachel R Deer; Demi Arnold; Kaitlin Dresser; Kenneth J Ottenbacher; James S Goodwin Journal: Arch Phys Med Rehabil Date: 2017-04-17 Impact factor: 3.966
Authors: Hanna van Waart; Martijn M Stuiver; Wim H van Harten; Edwin Geleijn; Marianne de Maaker-Berkhof; Jolanda Schrama; Maud M Geenen; Jetske M Meerum Terwogt; Simone M van den Heiligenberg; Jeannette A J H Hellendoorn-van Vreeswijk; Gabe S Sonke; Neil K Aaronson Journal: Int J Colorectal Dis Date: 2017-11-09 Impact factor: 2.571
Authors: Karen L Syrjala; Mark P Jensen; M Elena Mendoza; Jean C Yi; Hannah M Fisher; Francis J Keefe Journal: J Clin Oncol Date: 2014-05-05 Impact factor: 44.544
Authors: Shiraz I Mishra; Roberta W Scherer; Paula M Geigle; Debra R Berlanstein; Ozlem Topaloglu; Carolyn C Gotay; Claire Snyder Journal: Cochrane Database Syst Rev Date: 2012-08-15
Authors: Shiraz I Mishra; Roberta W Scherer; Claire Snyder; Paula M Geigle; Debra R Berlanstein; Ozlem Topaloglu Journal: Cochrane Database Syst Rev Date: 2012-08-15